(VIANEWS) – SOCIETE GENERALE (GLE.PA), MELEXIS (MELE.BR), BIC (BB.PA) are the highest payout ratio stocks on this list.
We have congregated information about stocks with the highest payout ratio up until now. The payout ratio in itself isn’t a guarantee of good investment but it’s an indicator of whether dividends are being paid and how the company chooses to issue them.
When investigating a potential investment, the dividend payout ratio is a good statistic to know so here are a few stocks with an above 30% percent payout ratio.
1. SOCIETE GENERALE (GLE.PA)
95.38% Payout Ratio
Société Générale Société anonyme provides banking and financial services to individuals, businesses, and institutional investors in Europe and internationally. It operates through French Retail Banking, International Retail Banking & Financial Services, and Global Banking and Investor Solutions. It offers retail banking services, such as consumer credit, vehicle leasing and fleet management, online banking, wealth management services, and equipment and vendor finance under the Societe Generale, Credit du Nord, and Boursorama brand names; and insurance products, including home, vehicle, family, health, and mortgage insurance. The company also provides corporate and investment banking, securities, business consulting, consumer finance, advisory and financing, and asset management and private banking services. In addition, it offers brokerage, cash management, payment, factoring, export financing, and supply chain financing services. Société Générale Société anonyme was incorporated in 1864 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, SOCIETE GENERALE has a trailing twelve months EPS of €1.74.
PE Ratio
SOCIETE GENERALE has a trailing twelve months price to earnings ratio of 12.85. Meaning, the purchaser of the share is investing €12.85 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.1%.
More news about SOCIETE GENERALE.
2. MELEXIS (MELE.BR)
53.28% Payout Ratio
Melexis NV designs, develops, tests, and markets advanced integrated semiconductor devices primarily for the automotive industry in Europe, the Middle-East, Africa, the Asia Pacific, and North and Latin America. The company provides magnetic position, latch and switch, current, inductive position, tire monitoring, temperature, optical, pressure, and speed sensor ICs. It also offers embedded motor driver, fan and pump, LED, and pre driver ICs; and LIN transceiver, CAN transceiver, RFID Transceiver NFC Sensor tag ICs. The company was founded in 1988 and is headquartered in Ieper, Belgium. Melexis NV is a subsidiary of Xtrion N.V.
Earnings Per Share
As for profitability, MELEXIS has a trailing twelve months EPS of €5.05.
PE Ratio
MELEXIS has a trailing twelve months price to earnings ratio of 19.59. Meaning, the purchaser of the share is investing €19.59 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 45.26%.
More news about MELEXIS.
3. BIC (BB.PA)
43.17% Payout Ratio
Société BIC SA manufactures and sells stationery, lighter, shaver, and other products worldwide. It offers ball and coloring felt pens, gel ink pens, markers, sticky notes, leads, whiteboards, and correction tapes, as well as graphite, coloring, mechanical, and other pencils; reusable notebooks, digital slates, and smart pens; art and craft kits; permanent and temporary tattoo markers; and pen and pencil refills. The company also provides refillable shavers and razors; and pocket, utility, and decorated lighters. In addition, it sells batteries and shaving preps; and advertising and promotional products. Further, the company is involved in the provision of delivery services; production of industrial equipment; and manufacture and distribution of IT solutions and consumer products, as well as in real estate and insurance activities. It markets its products primarily under the BIC, BIC Kids, Cello, Lucky, RocketBook, Tipp-Ex, BIC Wite-Out, Tattly, ami, DJEEP, InkBox, BIC Soleil, BIC Evolution, and BodyMark brands through a range of channels, including retail mass-market distributors, traditional stores, and office product stationers, as well as an e-commerce site. The company was founded in 1944 and is headquartered in Clichy, France.
Earnings Per Share
As for profitability, BIC has a trailing twelve months EPS of €4.71.
PE Ratio
BIC has a trailing twelve months price to earnings ratio of 12.44. Meaning, the purchaser of the share is investing €12.44 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.6%.
Sales Growth
BIC’s sales growth for the current quarter is negative 9.6%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 20.6%, now sitting on 2.23B for the twelve trailing months.
Yearly Top and Bottom Value
BIC’s stock is valued at €58.60 at 22:10 EST, way below its 52-week high of €70.60 and way higher than its 52-week low of €45.22.
More news about BIC.
4. TUBIZE-FIN (TUB.BR)
39.2% Payout Ratio
Financière de Tubize SA, through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Evenity, an injection for osteoporosis; and Bimzelx to treat moderate to severe plaque psoriasis. The company's products in pipeline include Staccato to treat stereotypical prolonged seizures; Bepranemab for the treatment of Alzheimer's disease; UCB0599 for Parkinson's disease; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, myelin oligodendrocyte glycoprotein antibody disease, and autoimmune encephalitis; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize SA is based in Brussels, Belgium.
Earnings Per Share
As for profitability, TUBIZE-FIN has a trailing twelve months EPS of €1.91.
PE Ratio
TUBIZE-FIN has a trailing twelve months price to earnings ratio of 41.52. Meaning, the purchaser of the share is investing €41.52 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.88%.
More news about TUBIZE-FIN.
